- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01086111
The Effect of a Gastric Bypass on Type 2 Diabetes in the Morbidly Obese Patient
Mechanisms of Type 2 Diabetes Improvement, Besides Weightloss After Gastric Bypass
Proof of concept, of RYGBP and its capabilities to cure type 2 diabetes (DM 2) and sleep apnea has already been recognized in the reports on weight loss surgery.
The investigators project aims to prove that RYGBP also recovers the beta cell function (BCF) Clamp tests, the gold standard for testing IS and BCF, will be performed preoperative and early postoperatively.
Aims & methodology:
Analysis of the short-term effect of gastric bypass and sleeve gastrectomy on insulin sensitivity and beta cell function.
Preoperative baseline insulin sensitivity and beta cell function will be assessed with euglycemic and hyperglycemic clamp tests. These results will be compared with the results of the same tests carried out 3 weeks postoperative.
To determine if the duodenal exclusion is causing this effect. The results of the clamp tests 3 weeks postoperative will be compared
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- University Hospitals Leuven, Gasthuisberg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female or male subjects aged 18 to 65
- BMI > 35 kg/m2
- Subject is capable and willing to give informed consent.
- In the surgical groups indication for surgery is approved by the local multidisciplinary obesity workgroup following the NIH guidelines of 199112.
- Patient suffers from type 2 diabetes necessitating insulin therapy.
- Subject is a non-smoker for at least 6 months prior to study start.
- Female patients of child bearing potential must use oral, injected or implanted hormonal methods of contraception from at least the commencement of their last normal period prior to the screening visit. Patients using hormonal contraception should use a barrier method in addition from screening visit until their next normal period following the end of the study.
Female patients of non-child bearing potential defined as:
- Post-menopausal females, being amenorrhoeic for at least 1 year
- Pre-menopausal females with a documented hysterectomy or bilateral oophorectomy.
Exclusion Criteria:
- Female patient is pregnant or breastfeeding.
- BMI < 35 kg/m2
- Patient suffers from an endocrine disease, besides diabetes and thyroid disease, such as Cushing's disease, Addison's disease, hypothalamic tumor…)
- Patient suffers from type 1 diabetes, MODY or LADA
- Patient has undergone previous surgical procedure for weight loss
- Patient is considered ASA 4 or more according to the ASA physical status classification system of the American Society of Anesthesiologists.
- Patient suffers from liver cirrhosis
- Patient uses steroids
- Patient uses cyclosporin
- Recent (<30 days) or simultaneous participation in another clinical trial.
- Any situation that can compromise the study, including serious illness or a predictable lack of cooperation from the subject.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
PMSF
type 2 diabetes patient receiving a protein sparing diet
|
sleeve gastrectomy
type 2 diabetes patient receiving a gastric bypass
|
RYGBP
type 2 diabetes patient receiving a gastric bypass
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
insulin sensitivity and beta cell function
Time Frame: 3 weeks
|
insulin sensitivity and beta cell function changes 3 weeks after RYGB, sleeve gastrectomy and protein sparing diet using euglycaemic and hyperglycemic clamp techniques.
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
changes in plasma levels of gut hormones and inflammation markers
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S51169
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted